Capricor Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
¡ -
Good afternoon. My name is Linda Marbán, and I am the CEO of Capricor Therapeutics. I want to thank the Alliance for Regenerative Medicine and the Meeting on the Mesa for hosting us today so that we can share with you the progress that we've made over the past year. This is a standard forward-looking statement slide. We are publicly traded, Nasdaq-listed under the symbol CAPR, and all of our filings are available on the SEC website.
So, I like to think of this slide sort of as the table of contents of what we're going to be discussing today. We're going to be talking about the two major product platforms that we have in our pipeline, our cell therapy product made from an allogeneic cell called CAP-1002, and our very exciting new exosome platform development program, which is going to be featuring engineered exosomes as well as exosomes made by our cells, the CDCs.
We have a strong balance sheet at this time with around $36 million in the bank. We have a long list of collaborators.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |